Jordan Food and Drug Administration (JFDA) concluded an initial draft to revise basis for drug pricing rules, in continuation of the Royal directives to make medicine accessible to all.

In a statement on Sunday, the JFDA said the move is part of its plan to study rules for drug prices and review the mechanism continuously, which would enhance drug security and provide medicines at affordable prices for citizens.

JFDA Director General , Nizar Mheidat, said amendments aimed to review price list of the reference drug pricing countries, and pick nations similar to Jordan's economic conditions, income level and population.

Moreover, he noted the plan aims to align with global pricing principles in force, taking into account the Kingdom's "distinctive" pharmaceutical market.

Mheidat added that amendments seek to study possibility of recalculating profit rates within multiple price categories, which would contribute to reducing drug prices.

Mheidat said the draft will contribute to expanding patient assistance program to include medicinal items for expensive chronic diseases drugs and launch mechanisms to support the local industry with regard to biological and developed medicines.